Drilldown: Medicines
Appearance
Medicines > classes
:
Antiparkinsonian
or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)
or
dissociative 
:
Antiparkinsonian
or
Selective 5HT2A inverse agonist (with weaker 5HT2C inverse agonism)
or
dissociative 
Use the filters below to narrow your results.
None (2) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-MeO-PCP (1) ·
Amantadine (1) ·
Apomorphine (1) ·
Benztropine (1) ·
Biperiden (1) ·
Bromocriptine (1) ·
Cabergoline (1) ·
Carbidopa/levodopa (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Entacapone (1) ·
Ephenidine (1) ·
Eticyclidine (1) ·
Ibogaine (1) ·
Levodopa (1) ·
Methoxetamine (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Opicapone (1) ·
Rasagiline (1) ·
Rotigotine (1) ·
Safinamide (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Selegiline (1) ·
Tolcapone (1) ·
Trihexyphenidyl (1) ·
Xenon (1)
None (18) ·
Akineton (1) ·
Apokyn (1) ·
Artane (1) ·
Azilect (1) ·
Cogentin (1) ·
Comtan (1) ·
Dostinex (1) ·
DXM (1) ·
DXO (1) ·
Eldepryl (1) ·
Neupro (1) ·
Nuplazid (1) ·
Ongentys (1) ·
Parlodel (1) ·
Sinemet (1) ·
Spravato (1) ·
Symmetrel (1) ·
Tasmar (1) ·
Xadago (1)
None (1) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Central and peripheral COMT inhibitor (1) ·
Contains salvinorin A (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist (3) ·
NMDA antagonist; dopamine releasing agent (1) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Selective inverse agonist at 5HT2A receptors with weaker activity at 5HT2C. Has no significant dopamine D2 affinity, unique among approved antipsychotics. Inverse agonism (rather than antagonism) reduces constitutive 5HT2A receptor activity below baseline. (1) ·
Selective M1 muscarinic antagonist (1)
None (35) ·
Hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Investigational for psychosis in other dementias and as augmentation for depression. (1) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
Showing below up to 37 results in range #1 to #37.

